Perennial Allergic Rhinitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Perennial Allergic Rhinitis – Drugs In Development, 2024 report and make more profitable business decisions.
Perennial rhinitis is an inflammatory condition that causes nasal congestion and runny nose. It is of two types: perennial allergic rhinitis and non-allergic rhinitis. Dust mites, pet dander, and mold are the most common allergens respoinsible for allergic rhinitis. Physical examination, blood or skin testing, and CT scan can be used for diagnosis. Management includes allergen avoidance along with pharmacological treatment. Corticosteroids, antihistamines, decongestants, anti-inflammatories, and allergen desensitization are treatment options.
The Perennial Allergic Rhinitis drugs in development market research report provide comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Perennial Allergic Rhinitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 8 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Perennial Allergic Rhinitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Perennial Allergic Rhinitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Perennial Allergic Rhinitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cellix Bio Pvt LtdDongKoo Bio & Pharma Co Ltd
Faes Farma SA
Johns Hopkins University
Palo Alto pharmaceuticals Inc
Roxall Medizin GmbH
The National Institute of Allergy and Infectious Diseases
Wuhan Yicheng Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Perennial Allergic Rhinitis reports